Haemonetics Stock Hits New 52-Week High (HAE)

NEW YORK ( TheStreet) -- Haemonetics Corporation (NYSE: HAE) hit a new 52-week high Monday as it is currently trading at $71.71, above its previous 52-week high of $71.50 with 48,128 shares traded as of 9:45 a.m. ET. Average volume has been 109,400 shares over the past 30 days.

Haemonetics has a market cap of $1.72 billion and is part of the health care sector and health services industry.

Haemonetics Corporation develops and manufactures automated blood component collection devices and surgical blood salvage devices to plasma and blood collectors, hospitals, and health care providers.

TheStreet Ratings rates Haemonetics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Haemonetics Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.